Enzon Extends Exchange Offer Amid Pending Viskase Merger

Enzon Pharmaceuticals ( (ENZN) ) just unveiled an update.

On March 9, 2026, Enzon Pharmaceuticals announced it had extended the expiration date of its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock, who are being offered Enzon common shares in exchange. The offer will now expire one minute after 11:59 p.m. Eastern time on March 11, 2026, unless extended again, giving preferred shareholders additional time to participate in the stock-for-stock exchange.

The exchange offer is being conducted alongside Enzon’s proposed merger with Viskase Companies, Inc., for which Enzon has filed a registration statement on Form S-4 containing financial information about the combined company. The disclosure underscores that the deal remains subject to customary closing conditions and regulatory and shareholder approvals, highlighting ongoing uncertainty for investors around timing, ownership structure and future performance of the combined entity.

More about Enzon Pharmaceuticals

Enzon Pharmaceuticals operates in the pharmaceutical and biotechnology sector, with its capital structure including Series C Non-Convertible Redeemable Preferred Stock and common stock. The company is currently engaged in a proposed merger transaction with Viskase Companies, Inc., for which it has filed a registration statement with the U.S. Securities and Exchange Commission.

Average Trading Volume: 70,006

Technical Sentiment Signal: Sell

Current Market Cap: $4.45M

For an in-depth examination of ENZN stock, go to TipRanks’ Overview page.